Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Ezekowitz

Showing results (61-70 of 187) with videos related to

Pageof 19
Sort By:
Stroke|April 12, 2012
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trialRobert G Hart, Hans-Christoph Diener, Sean Yang, et al.
Thrombosis and Haemostasis|January 29, 2016
D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudyAgneta Siegbahn, Jonas Oldgren, Ulrika Andersson, et al.
American Heart Journal|April 21, 2009
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatranMichael D Ezekowitz, Stuart Connolly, Amit Parekh, et al.
American Heart Journal|December 19, 2015
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillationJulia Aulin, Agneta Siegbahn, Ziad Hijazi, et al.
European Heart Journal|March 15, 2005
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trialAnders G Olsson, Gregory G Schwartz, Michael Szarek, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|April 26, 2008
Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbitsEmmanuelle Jeanpierre, Thierry Le Tourneau, Christophe Zawadzki, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 22, 2015
Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trialStefan H Hohnloser, Riccardo Cappato, Michael D Ezekowitz, et al.
The American Journal of Medicine|June 6, 2016
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial FibrillationGiulia Renda, Marco Zimarino, Fabrizio Ricci, et al.
American Heart Journal|September 7, 2016
Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trialMichael D Ezekowitz, Charles V Pollack, Paul Sanders, et al.
The Neurohospitalist|June 22, 2017
Internal Carotid Artery and Sphenoidal Emissary (Vesalian) Vein Fistula Mimicking a Carotid-Cavernous Sinus FistulaAva L Liberman, Preethi Ramchand, Kimberly Gannon, et al.
Pageof 19

Showing results (61-70 of 187) with videos related to

Sort By:
Pageof 19
Stroke|April 12, 2012
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trialRobert G Hart, Hans-Christoph Diener, Sean Yang, et al.
Thrombosis and Haemostasis|January 29, 2016
D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudyAgneta Siegbahn, Jonas Oldgren, Ulrika Andersson, et al.
American Heart Journal|April 21, 2009
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatranMichael D Ezekowitz, Stuart Connolly, Amit Parekh, et al.
American Heart Journal|December 19, 2015
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillationJulia Aulin, Agneta Siegbahn, Ziad Hijazi, et al.
European Heart Journal|March 15, 2005
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trialAnders G Olsson, Gregory G Schwartz, Michael Szarek, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|April 26, 2008
Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbitsEmmanuelle Jeanpierre, Thierry Le Tourneau, Christophe Zawadzki, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 22, 2015
Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trialStefan H Hohnloser, Riccardo Cappato, Michael D Ezekowitz, et al.
The American Journal of Medicine|June 6, 2016
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial FibrillationGiulia Renda, Marco Zimarino, Fabrizio Ricci, et al.
American Heart Journal|September 7, 2016
Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trialMichael D Ezekowitz, Charles V Pollack, Paul Sanders, et al.
The Neurohospitalist|June 22, 2017
Internal Carotid Artery and Sphenoidal Emissary (Vesalian) Vein Fistula Mimicking a Carotid-Cavernous Sinus FistulaAva L Liberman, Preethi Ramchand, Kimberly Gannon, et al.
Pageof 19